Canaccord Genuity Group Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $79.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by Canaccord Genuity Group from $128.00 to $79.00 in a research report report published on Wednesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on RARE. Wedbush restated a “neutral” rating and issued a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday. Bank of America cut their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. TD Cowen reduced their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Guggenheim decreased their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Finally, Robert W. Baird reduced their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $68.29.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $22.72 on Wednesday. The company has a market capitalization of $2.20 billion, a PE ratio of -3.89 and a beta of 0.16. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $45.00. The firm has a 50 day moving average price of $25.40 and a 200 day moving average price of $29.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. During the same quarter last year, the company earned ($1.39) earnings per share. The firm’s revenue for the quarter was up 25.5% on a year-over-year basis. As a group, equities research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 3,081 shares of the company’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total value of $112,086.78. Following the completion of the sale, the chief financial officer owned 95,146 shares in the company, valued at $3,461,411.48. This represents a 3.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 6,227 shares of company stock valued at $187,126. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after buying an additional 29,984 shares during the last quarter. CWM LLC grew its stake in shares of Ultragenyx Pharmaceutical by 1,171.2% in the 2nd quarter. CWM LLC now owns 4,144 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 3,818 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Ultragenyx Pharmaceutical by 59.8% in the second quarter. Nordea Investment Management AB now owns 60,176 shares of the biopharmaceutical company’s stock valued at $2,208,000 after purchasing an additional 22,509 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $715,000. Finally, Ethic Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $241,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Analyst support and updated estimates: HC Wainwright reiterated a Buy and updated / raised multi‑quarter and FY‑2027 EPS forecasts, keeping a $50 target — a positive signal for future earnings trajectory and investor sentiment. HC Wainwright price target and estimates
• Positive Sentiment: Inducement RSU grants to new hires: Ultragenyx granted 22,917 restricted stock units to six newly hired non‑executive officers (vesting over four years) under its Employment Inducement Plan — indicates investment in talent for development/commercialization execution. Ultragenyx Reports Inducement Grant
• Neutral Sentiment: Mixed sell‑side views: Wedbush reiterated a Neutral rating while other outlets published a range of analyst price targets (median cited around $55) — keeps the stock in focus but provides no clear directional catalyst by itself. Wedbush reiterates Neutral
• Negative Sentiment: Ongoing securities‑class action notices and lead‑plaintiff deadlines: Multiple firms (Kessler Topaz, Schall, Faruqi, Pomerantz, Robbins Geller, Levi & Korsinsky, Rosen, etc.) are soliciting Ultragenyx investors in a suit covering Aug 3, 2023–Dec 26, 2025 with an April 6, 2026 lead‑plaintiff deadline — increases legal overhang and potential future liability. RARE Investor Alert: Kessler Topaz
• Negative Sentiment: Insider selling and institutional positioning: Recent filings highlighted insider sales (multiple officers) and mixed hedge fund moves (notable large reductions by some institutions) — potential signal of near‑term selling pressure or rebalancing. QuiverQuant summary (includes insider activity)
• Negative Sentiment: Pessimistic sell‑side note: Canaccord published a pessimistic forecast for RARE, adding downside analytical pressure amid mixed institutional flows and legal risk. Canaccord Genuity pessimistic forecast

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.